Influenza vaccination in the elderly: Is a trial on mortality ethically acceptable?

Area of Science:

• Gerontology
• Vaccinology
• Bioethics

Background:

• The effectiveness of influenza vaccination in the elderly, particularly regarding mortality, remains debated due to limited direct evidence from randomized trials.
• Observational studies suggest benefits, but methodological limitations fuel uncertainty and calls for new placebo-controlled trials.

Purpose of the Study:

• To provide a comprehensive overview of the ethical challenges associated with conducting influenza vaccine efficacy trials focused on mortality in the elderly.
• To analyze the ethical justification and feasibility of new placebo-controlled trials in this population.

Main Methods:

• Extensive analysis of existing knowledge regarding influenza vaccine effectiveness in the elderly.
• Evaluation of ethical principles, including clinical equipoise and the Declaration of Helsinki, in the context of vaccine trials.
• Assessment of methodological barriers for potential trial designs, such as placebo-controlled trials in vaccine refusers.

Main Results:

• Genuine uncertainty is a prerequisite for trials, requiring thorough knowledge assessment. Withholding vaccination, considered competent care, poses ethical issues even with clinical equipoise.
• The high disease burden and proven benefits of vaccination make it unlikely that new trials would meet the ethical threshold of outweighing patient risks.
• Placebo-controlled trials in vaccine refusers face significant methodological hurdles in terms of sample size and generalizability.

Conclusions:

• New trials are unlikely to provide definitive answers or alter current influenza vaccination policy for the elderly.
• Researchers considering such trials must carefully address the discussed ethical challenges due to the lack of consensus on their acceptability.